一名明显骨髓纤维化患者在fedratinib治疗失败后ruxolitinib再治疗成功。 - Suppr | 超能文献

相似文献

1

Successful ruxolitinib rechallenge after fedratinib failure in a patient with overt myelofibrosis.一名明显骨髓纤维化患者在fedratinib治疗失败后ruxolitinib再治疗成功。

Ann Hematol. 2024 Nov;103(11):4817-4819. doi: 10.1007/s00277-024-05825-6. Epub 2024 Aug 2.

2

Management of myelofibrosis after ruxolitinib failure.芦可替尼治疗失败后的骨髓纤维化的管理。

Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20.

3

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.在既往接受过鲁索替尼治疗的骨髓纤维化患者中使用Janus激酶2抑制剂非格司亭（JAKARTA-2）：一项单臂、开放标签、非随机、2期、多中心研究。

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

4

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.非格司亭用于既往接受过鲁索替尼治疗的骨髓纤维化患者的疗效和安全性（FREEDOM2）：一项多中心、开放标签、随机、对照、3期试验的结果

Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9.

5

Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.既往接受鲁索替尼治疗失败后的骨髓纤维化患者应用 Fedratinib 的真实世界应用：患者特征、治疗模式和临床结局。

Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):122-132. doi: 10.1016/j.clml.2023.09.008. Epub 2023 Sep 29.

6

Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study.fedratinib用于芦可替尼耐药或难治的真性红细胞增多症初发及继发患者或原发性血小板增多症骨髓纤维化常规治疗的疗效：一项全国性回顾性研究

Acta Haematol. 2024 Sep 12:1-7. doi: 10.1159/000540906.

7

Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.Fedratinib，首个获批用于治疗骨髓纤维化的选择性 JAK2 抑制剂——鲁索替尼之外的另一种选择。

Expert Rev Hematol. 2022 Jul;15(7):583-595. doi: 10.1080/17474086.2022.2098105. Epub 2022 Jul 11.

8

Would you like to take some more ruxolitinib after your fedratinib?在服用fedratinib之后，你还想再服用一些鲁索替尼吗？

Br J Haematol. 2024 Oct;205(4):1253-1254. doi: 10.1111/bjh.19695. Epub 2024 Aug 14.

9

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.非格司亭改善曾接受鲁索替尼治疗的骨髓纤维化患者的骨髓纤维化相关症状及健康相关生活质量：II期JAKARTA2试验的患者报告结局

Hemasphere. 2021 Apr 29;5(5):e562. doi: 10.1097/HS9.0000000000000562. eCollection 2021 May.

10

Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.接受 fedratinib 治疗的因原发性骨髓纤维化而停止使用 ruxolitinib 的患者的真实世界结局。

Future Oncol. 2024;20(17):1165-1174. doi: 10.2217/fon-2022-1256. Epub 2023 Nov 22.

本文引用的文献

1

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.原发性骨髓纤维化：2023年诊断、风险分层及管理的最新进展

Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6.

2

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.芦可替尼再治疗骨髓纤维化患者：患者特征和结局的真实世界证据。

Acta Haematol. 2022;145(4):448-453. doi: 10.1159/000520440. Epub 2022 Jan 10.

3

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.